ストックスクリーナーアプリを入手
1.97
1.03%
0.02
アフターアワーズ：
2.02
0.05
+2.54%
前日終値:
$1.95
開ける：
$1.99
24時間の取引高:
2.27M
Relative Volume:
1.58
時価総額：
$140.96M
収益：
-
当期純損益:
-
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
-
1週間 パフォーマンス:
+28.76%
1か月 パフォーマンス:
-28.62%
6か月 パフォーマンス:
+57.60%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$1.95
$2.3791
1週間の範囲:
$1.47
$2.3791
52週間の値動き範囲:
$0.5506
$6.19
Citius Oncology Inc Stock (CTOR) Company Profile
CTOR を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CTOR
Citius Oncology Inc
|
1.97 | 152.82M | 0 | 0 | 0 | 0.00 |
|
ZTS
Zoetis Inc
|
152.12 | 68.04B | 9.29B | 2.52B | 2.28B | 5.57 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.48 | 46.30B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
HLN
Haleon Plc Adr
|
9.88 | 44.25B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.54 | 18.73B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
304.50 | 13.82B | 2.99B | 1.21B | 1.13B | 25.06 |
Citius Oncology Inc Stock (CTOR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-11-27 | 開始されました | Maxim Group | Buy |
Citius Oncology Inc (CTOR) 最新ニュース
Is Citius Oncology Inc. a good long term investmentExceptional trading performance - Autocar Professional
Citius Oncology Announces Closing of $9.0 Million Public Offering - StreetInsider
Citius Oncology Inc. Stock Analysis and ForecastMarket-leading capital gains - Autocar Professional
What drives Citius Oncology Inc. stock priceConsistently exceptional gains - Autocar Professional
What analysts say about Citius Oncology Inc. stockFree Wealth Management Insights - jammulinksnews.com
Citius Oncology shares rise 1.31% after-hours after closing a $9.0 million public offering. - AInvest
Should I buy Citius Oncology Inc. stock before earningsShort Term High Return Strategy - Newser
Citius Oncology Completes $9M Public Offering - TipRanks
Citius Oncology launches $15M equity and warrant offering; shares down - MSN
Citius Oncology closes $9 million public offering to support LYMPHIR - Investing.com Australia
Citius Oncology closes $9 million public offering to support LYMPHIR By Investing.com - Investing.com Nigeria
Citius Oncology Raises $9M in Public Offering for LYMPHIR Commercialization - AInvest
Citius Oncology Announces Closing Of $9.0 Million Public Offering - Barchart.com
Citius Oncology Announces Pricing Of $9M "Reasonable Best-Efforts" Public Offering Of 6,818,182 Shares Of Common Stock And Warrants To Purchase Shares Of Common Stock At A Public Offering Price Of $1.32 Per Share - 富途牛牛
Citius Pharmaceuticals shares fall 1.34% after-hours following Citius Oncology's public offering. - AInvest
Citius Oncology’s Chances: Time to Invest? - StocksToTrade
Citius Oncology Announces Pricing of $9.0 Million Public Offering - Finansavisen
Citius Oncology Soars 35.06% on Distribution Deal - AInvest
Citius Oncology Soars 12.34% on Expanded Lymphir Distribution - AInvest
Citius Oncology stock rises after expanding LYMPHIR distribution network - Investing.com
What makes Citius Oncology Inc. stock price move sharplySecure Your Capital Strategy - Newser
Why Citius Oncology Inc. stock attracts strong analyst attentionEarly Breakout Tracker - Newser
Cencora (COR) Partners With Citius Oncology For Immunotherapy Distribution Expansion - simplywall.st
Citius Oncology Shares Climb Following Expansion of LYMPHIR Distribution Network - MSN
Citius Oncology (CTOR): Is LYMPHIR's Launch Priced for Success? - AInvest
Citius Oncology: Is A Lymphir Launch Coming Too Late? - Seeking Alpha
Citius Pharmaceuticals (CTXR) Surges on New Distribution Deal - GuruFocus
Citius Oncology stock rises after expanding LYMPHIR distribution network By Investing.com - Investing.com South Africa
How Citius Oncology Inc. stock performs during market volatilityLow Risk Entry Points - Newser
Citius Oncology Expands Lymphir Distribution With Cencora - MarketScreener
Cencora distribution deal boosts Citius shares - MSN
Citius Oncology expands distribution network for LYMPHIR with Cencora - Investing.com Australia
Citius Oncology expands distribution network for LYMPHIR with Cencora By Investing.com - Investing.com India
Citius stock gains on Cencora distribution deal (CTXR:NASDAQ) - Seeking Alpha
Citius Oncology Inc (CTOR) 財務データ
Citius Oncology Inc (CTOR) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
2.82%
0.27%
大文字化:
|
ボリューム (24 時間):